HK1200876A1 - A single nucleotide polymorphism on chromosome 15 that predicts hcv treatment responses hcv 15 - Google Patents

A single nucleotide polymorphism on chromosome 15 that predicts hcv treatment responses hcv 15

Info

Publication number
HK1200876A1
HK1200876A1 HK15101211.4A HK15101211A HK1200876A1 HK 1200876 A1 HK1200876 A1 HK 1200876A1 HK 15101211 A HK15101211 A HK 15101211A HK 1200876 A1 HK1200876 A1 HK 1200876A1
Authority
HK
Hong Kong
Prior art keywords
hcv
predicts
chromosome
single nucleotide
nucleotide polymorphism
Prior art date
Application number
HK15101211.4A
Other languages
English (en)
Chinese (zh)
Inventor
Ryma Benayed
Laurent Essioux
Mercidita T Navarro
Giuseppe Palermo
Bridget Riley-Gillis
Yonghong Zhu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1200876A1 publication Critical patent/HK1200876A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15101211.4A 2011-11-28 2015-02-04 A single nucleotide polymorphism on chromosome 15 that predicts hcv treatment responses hcv 15 HK1200876A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161564032P 2011-11-28 2011-11-28
PCT/EP2012/073554 WO2013079424A1 (en) 2011-11-28 2012-11-26 A single nucleotide polymorphism on chromosome 15 that predicts hcv treatment responses

Publications (1)

Publication Number Publication Date
HK1200876A1 true HK1200876A1 (en) 2015-08-14

Family

ID=47221425

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101211.4A HK1200876A1 (en) 2011-11-28 2015-02-04 A single nucleotide polymorphism on chromosome 15 that predicts hcv treatment responses hcv 15

Country Status (12)

Country Link
US (1) US20130137084A1 (ru)
EP (1) EP2785875B1 (ru)
JP (1) JP5834146B2 (ru)
KR (1) KR101656158B1 (ru)
CN (1) CN103987862B (ru)
BR (1) BR112014012886A2 (ru)
CA (1) CA2850904C (ru)
ES (1) ES2573500T3 (ru)
HK (1) HK1200876A1 (ru)
MX (1) MX349879B (ru)
RU (1) RU2606759C2 (ru)
WO (1) WO2013079424A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CH707029B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Verfahren zur Behandlung von HCV, umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin, aber nicht Interferon.
AU2013201532B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
CN105463084B (zh) * 2015-12-11 2019-04-12 上海新培晶医学检验所有限公司 一种检测白介素28b三个snp位点基因型的试剂盒及其检测方法
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
RU2287825C1 (ru) * 2005-07-25 2006-11-20 Александр Валентинович Ягода СПОСОБ ПРОГНОЗИРОВАНИЯ РЕЗУЛЬТАТОВ ЛЕЧЕНИЯ БОЛЬНЫХ ХРОНИЧЕСКИМ ВИРУСНЫМ ГЕПАТИТОМ С ПРЕПАРАТАМИ ИНТЕРФЕРОНА-α
CA2735439A1 (en) * 2008-08-28 2010-03-04 Vertex Pharmaceuticals Incorporated Analysis of hcv genotypes
EP2379745A1 (en) * 2008-12-18 2011-10-26 F. Hoffmann-La Roche AG Biomarkers for hcv treatment response
MX2012005528A (es) * 2009-11-14 2012-06-12 Hoffmann La Roche Biomarcadores para pronosticar rapida respuesta a tratamiento hcv.
CA2795911A1 (en) * 2010-04-13 2011-10-20 F. Hoffmann-La Roche Ag Single nucleotide polymorphisms that predict hcv treatment outcomes
BR112012026124A2 (pt) * 2010-04-13 2016-11-22 Hoffmann La Roche previsão de resposta virológica precoce no tratamento de hcv
IT1399564B1 (it) * 2010-04-16 2013-04-19 Metzeler Automotive Profile Guarnizione di tenuta per un autoveicolo, e procedimento per la sua fabbricazione
US20120196272A1 (en) * 2010-08-05 2012-08-02 Roche Molecular Systems, Inc. Prediction of HCV Viral Kinetics in Interferon-Free Treatment

Also Published As

Publication number Publication date
KR101656158B1 (ko) 2016-09-08
KR20140088168A (ko) 2014-07-09
JP2014533108A (ja) 2014-12-11
EP2785875B1 (en) 2016-04-27
CN103987862A (zh) 2014-08-13
CN103987862B (zh) 2016-05-25
RU2014124032A (ru) 2016-01-27
RU2606759C2 (ru) 2017-01-10
MX2014006185A (es) 2014-07-10
CA2850904C (en) 2018-10-02
EP2785875A1 (en) 2014-10-08
ES2573500T3 (es) 2016-06-08
JP5834146B2 (ja) 2015-12-16
MX349879B (es) 2017-08-16
CA2850904A1 (en) 2013-06-06
WO2013079424A1 (en) 2013-06-06
BR112014012886A2 (pt) 2017-06-13
US20130137084A1 (en) 2013-05-30

Similar Documents

Publication Publication Date Title
HK1216254A1 (zh) 取代的核苷酸類似物
HK1200876A1 (en) A single nucleotide polymorphism on chromosome 15 that predicts hcv treatment responses hcv 15
HK1203075A1 (en) Substituted phosphorothioate nucleotide analogs
IL231983B (en) Dna containing tricyclo-phosphorothioate
IL227842A0 (en) Non-invasive methods for determining ploidy before birth
ZA201307225B (en) Methods for genomic modification
IL231535A0 (en) Multimeric oligonucleotide compounds
ZA201205891B (en) Dna polymerases
IL221029A0 (en) Targeted genomic alteration
EP2847353A4 (en) METHOD FOR DETERMINING A NUCLEOTIDE SEQUENCE
EP2652632A4 (en) SUPPORT FOR DISTRIBUTED KEY-BASED PROCESSES
IL222504A (en) Xylan isomerization process
EP2688717A4 (en) TELEMANIPULATOR SYSTEM HAVING DEXTERITY
GB201118636D0 (en) Nucleotide sequence
EP2776574B8 (en) Methods for determining nucleotide sequence repeats
HK1198704A1 (zh) 具有改進活性的 聚合酶
HK1186215A1 (zh) 基因分型
EP2686822A4 (en) SUPPORT SYSTEM FOR CLINICAL DECISION MAKING
PT2535424E (pt) Snps associados a doença tromboembólica
EP2717400A4 (en) EYELET
EP2786146A4 (en) SINGLE-NUCLEOTIDE POLYMORPHISM ASSAY HIGH-PERFORMANCE
EP2778668A4 (en) MULTI-REACTION BIOSENSOR
EP2664917A4 (en) METHOD FOR DETECTION OF MONOBASIC POLYMORPHISM
HK1197075A1 (en) Hcv genotype 3 replicons hcv 3
HK1197074A1 (en) Hcv genotype 4 replicons hcv 4

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20201122